Drugging the Undruggable: Advances on RAS Targeting in Cancer.

Genes (Basel) · 2021 · PMC8228461 · PMID 34200676

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

An exploratory analysis of co-mutations in a clinical trial cohort showed a trend toward a higher response rate in STK11-co-mutated tumours (64 vs. 33% in WT), while, conversely, KEAP1 and TP53 co-mutations were not predictive of response [ 84 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.